Not specified Not specified
Not specified (Nasdaq: Not specified) is a respiratory drug developer. Its lead program, IHL-42X, is in Phase 2 for Obstructive sleep apnea. Its next catalyst on record is IHL-42X: DReAMzz Study completion (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IHL-42X — DReAMzz Study completion (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IHL-42X | Obstructive sleep apnea | small molecule | Phase 2 |
| PSX-001 | Generalized anxiety disorder | small molecule | Phase 2 |
| IHL-675A | Rheumatoid arthritis / inflammatory conditions | small molecule | Phase 1 |
Recent results and decisions
- Aug 25, 2026started First patient dosed in the DReAMzz Phase 2 crossover dose-optimization study of IHL-42X in obstructive sleep apnea.
today announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, the Company’s oral fixed-dose combination drug candidate for the treatment of obstructive sleep apnea (“OSA”).
Filing - Apr 22, 2026met Completed 73-patient Phase 2 of PSX-001 in GAD recapped: 12.8-point HAM-A reduction vs 3.6 for placebo (p<0.0001), 44% response, 27% remission, no serious adverse events.
In Incannex’s completed Phase 2 clinical trial, PSX-001 demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints:
Filing - Dec 3, 2025n/a FDA granted Fast Track designation to IHL-42X for obstructive sleep apnea (a designation, not an approval or hold decision); written FDA feedback on Phase 2 package still expected.
Incannex Healthcare Inc. announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.